
Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS
The European Commission (EC) has granted marketing authorization for imetelstat (Rytelo) as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low-, low-, or intermediate-risk myelodysplastic syndrome (MDS) who …